Bionano Genomics (BNGO) shares fell nearly 8% in recent Thursday trading after the company lowered its Q3 revenue guidance.
The healthcare company slashed its Q3 revenue forecast to between $6.5 million and $6.8 million from a prior outlook of $7.9 million to $8.9 million.
Analysts polled by S&P Capital IQ expect $7.9 million.
Bionano added that it had $23.3 million in cash, cash equivalents, available-for-sale securities, and restricted cash as of Sept. 30, of which $11.4 million was subject to certain restrictions.
The company "has been undertaking a strategic shift in the business that is intended to allow us to become a more capital-efficient business focused on driving utilization and adoption of [optical genome mapping] from our existing installed base, with less emphasis on new placements of our [optical genome mapping] systems. This business transformation may be a factor in revenues coming in lighter than previously anticipated," Bionano Chief Executive Erik Holmlin said in a statement.
Price: 0.39, Change: -0.03, Percent Change: -7.73
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.